A phase I study of docetaxel (Taxotere), carboplatin, and gemcitabine (DoCaGem) as first-line therapy for patients with high-risk epithelial tumors of mullerian origin

Trial Profile

A phase I study of docetaxel (Taxotere), carboplatin, and gemcitabine (DoCaGem) as first-line therapy for patients with high-risk epithelial tumors of mullerian origin

Completed
Phase of Trial: Phase I

Latest Information Update: 25 Jun 2013

At a glance

  • Drugs Docetaxel (Primary) ; Gemcitabine (Primary) ; Carboplatin
  • Indications Endometrial cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 13 Oct 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top